Budesonide CAS NO.51333-22-3

Form

Color

1. Induce the synthesis of lipocortin to inhibit phospholipase A2, reducing the production and release of lipid inflammatory mediators such as platelet activating factor, leukotrienes, prostaglandins, etc., which are generated by the hydrolysis of membrane phospholipids catalyzed by this enzyme.

2. Induce the expression of angiotensin I converting enzyme and neutral endopeptidase, accelerating the generation of angiotensin II and the degradation and inactivation of bradykinin and tachykinin respectively; inhibit the expression of nitric oxide synthase, reducing the production of nitric oxide. Thus, it can constrict blood vessels or alleviate the effects of many other active substances except angiotensin II, such as dilating blood vessels, causing inflammation, and inducing neurogenic inflammatory reactions, etc. Chemicalbook. In addition, it can also induce the production of the vasoconstrictive substance vasocortin.

3. Inhibit the expression of a variety of cytokines, such as interleukin 1, 3, 4, 6, 8, tumor necrosis factor, and granulocyte colony-stimulating factor. Mitigate the effects of the above factors in airway inflammation, especially chronic inflammation.

4. Promote the expression of the β2-adrenergic receptor, increasing the sensitivity to endogenous and exogenous β2-adrenergic agonists.

5. Immunosuppressive effect: It has an inhibitory effect on the entire immune process, from the phagocytosis and processing of antigens, the proliferation and differentiation of lymphocytes, to the effector phase.